The Association for the Accreditation of Human Research Protection Programs today announced that it has awarded accreditation to five more organizations
The Association for the Accreditation of Human Research Protection Programs today announced that it has awarded accreditation to five more organizations, including institutions in Seoul, Republic of Korea; Nanjing, China; Michigan; New York and Louisiana. The newly accredited organizations are:
“These latest accreditations demonstrate the increasing recognition that AAHRPP accreditation is the mark of excellence for human research protection programs, here and around the globe,” said Elyse Summers, AAHRPP president and CEO. “AAHRPP accreditation signifies an organization’s commitment to the highest level of research protections—all to the benefit of the research participants we are pledged to protect.”
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. Accreditation decisions are made quarterly. They continue at a steady pace, reflecting strong interest in every sector of the research enterprise, in the U.S. and abroad.
To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Mexico, Republic of Korea, Singapore and Taiwan. All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 60 percent of U.S. research-intensive universities and 65 percent of U.S. medical schools are either AAHRPP accredited or have begun the accreditation process.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.